Ophthotech (OPHT) Is At $2.75 Formed Wedge; Perceptive Advisors Has Lifted By $156.31 Million Its Alnylam Pharmaceuticals (ALNY) Holding

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Ophthotech Corporation (OPHT) formed wedge down with $2.59 target or 6.00% below today’s $2.75 share price. Ophthotech Corporation (OPHT) has $99.52M valuation. The stock increased 1.66% or $0.05 during the last trading session, reaching $2.75. About 243,694 shares traded or 28.75% up from the average. Ophthotech Corporation (NASDAQ:OPHT) has declined 26.03% since May 16, 2017 and is downtrending. It has underperformed by 37.58% the S&P500.

Perceptive Advisors Llc increased Alnylam Pharmaceuticals Inc (ALNY) stake by 1230.8% reported in 2017Q4 SEC filing. Perceptive Advisors Llc acquired 1.23 million shares as Alnylam Pharmaceuticals Inc (ALNY)’s stock rose 5.82%. The Perceptive Advisors Llc holds 1.33M shares with $169.08 million value, up from 100,000 last quarter. Alnylam Pharmaceuticals Inc now has $10.25B valuation. The stock decreased 1.11% or $1.14 during the last trading session, reaching $101.99. About 732,117 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 150.73% since May 16, 2017 and is uptrending. It has outperformed by 139.18% the S&P500.

Since January 4, 2018, it had 0 insider buys, and 10 sales for $38.04 million activity. Vaishnaw Akshay had sold 88,554 shares worth $12.67M. KEATING LAURIE had sold 20,000 shares worth $2.90M on Monday, March 12. Greenstreet Yvonne sold $985,958 worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Monday, March 26. The insider SCHIMMEL PAUL sold 27,823 shares worth $4.17 million. Ausiello Dennis A sold $2.57 million worth of stock. $4.84 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was sold by Mason Michael. SHARP PHILIP A also sold $2.24M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares.

Among 24 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Alnylam Pharmaceuticals had 107 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Overweight” rating by Barclays Capital on Thursday, September 7. As per Wednesday, January 20, the company rating was initiated by Credit Suisse. As per Friday, March 11, the company rating was upgraded by JP Morgan. Goldman Sachs maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, October 6. Goldman Sachs has “Neutral” rating and $34 target. The firm earned “Buy” rating on Monday, December 11 by FBR Capital. Needham maintained it with “Buy” rating and $9800 target in Monday, June 26 report. Morgan Stanley initiated Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Tuesday, August 2. Morgan Stanley has “Overweight” rating and $93 target. FBR Capital maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Friday, February 16. FBR Capital has “Buy” rating and $200.0 target. The firm has “Hold” rating given on Friday, May 4 by Stifel Nicolaus. The firm earned “Equal-Weight” rating on Thursday, October 6 by Barclays Capital.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Alnylam Pharmaceuticals: Hitting The Next Growth Curve” on April 25, 2018, also Seekingalpha.com with their article: “Alnylam Pharmaceuticals (ALNY) Q1 2018 Results – Earnings Call Transcript” published on May 04, 2018, Nasdaq.com published: “Ionis Pharmaceuticals Prepares for Launch” on May 09, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Businesswire.com and their article: “Alnylam Appoints Colleen Reitan to the Board of Directors” published on May 15, 2018 as well as Fool.com‘s news article titled: “Alnylam Looks Forward” with publication date: May 08, 2018.

Perceptive Advisors Llc decreased Tesaro Inc (NASDAQ:TSRO) stake by 259,279 shares to 129,372 valued at $10.72M in 2017Q4. It also reduced Biohaven Pharmactl Hldg Co L stake by 45,000 shares and now owns 261,134 shares. Abeona Therapeutics Inc was reduced too.

Investors sentiment increased to 2.03 in Q4 2017. Its up 1.11, from 0.92 in 2017Q3. It is positive, as 27 investors sold ALNY shares while 47 reduced holdings. 67 funds opened positions while 83 raised stakes. 90.18 million shares or 4.83% more from 86.02 million shares in 2017Q3 were reported. Rhenman & Asset owns 58,967 shares. 9,400 are owned by Sector Gamma As. Moreover, Wellington Management Gp Llp has 0.26% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Laurion Management LP holds 0.08% or 121,735 shares in its portfolio. Ubs Asset Mgmt Americas Inc holds 0.15% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 1.39 million shares. State Of Alaska Department Of Revenue stated it has 6,300 shares. Barclays Pcl stated it has 85,544 shares or 0.01% of all its holdings. Rock Springs Cap Mgmt Lp owns 130,000 shares or 0.75% of their US portfolio. Fmr Lc holds 0.22% or 14.88M shares. Hall Laurie J Trustee invested in 0.28% or 3,800 shares. Architects has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Weiss Asset Mgmt LP holds 0.03% or 2,460 shares in its portfolio. Fjarde Ap holds 0.06% or 29,285 shares in its portfolio. Price T Rowe Associate Inc Md, a Maryland-based fund reported 12.23 million shares. Moreover, Winfield Inc has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 5 shares.

Since December 29, 2017, it had 0 insider buys, and 9 insider sales for $126,644 activity. 16,520 shares were sold by GUYER DAVID R, worth $52,699 on Friday, December 29. WOOD BARBARA A also sold $1,908 worth of Ophthotech Corporation (NASDAQ:OPHT) on Thursday, January 4. SBLENDORIO GLENN also sold $18,394 worth of Ophthotech Corporation (NASDAQ:OPHT) shares. Another trade for 317 shares valued at $1,005 was sold by Westby Keith.

Among 13 analysts covering Ophthotech Corporation (NASDAQ:OPHT), 2 have Buy rating, 2 Sell and 9 Hold. Therefore 15% are positive. Ophthotech Corporation had 29 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Tuesday, December 13 by Gabelli. The rating was upgraded by Goldman Sachs on Tuesday, December 13 to “Neutral”. The stock of Ophthotech Corporation (NASDAQ:OPHT) earned “Neutral” rating by Chardan Capital Markets on Wednesday, February 28. As per Monday, December 12, the company rating was downgraded by Cowen & Co. As per Thursday, January 7, the company rating was initiated by SunTrust. The stock of Ophthotech Corporation (NASDAQ:OPHT) earned “Hold” rating by Stifel Nicolaus on Friday, October 27. The stock of Ophthotech Corporation (NASDAQ:OPHT) has “Neutral” rating given on Monday, December 12 by Chardan Capital Markets. The rating was downgraded by Goldman Sachs to “Sell” on Friday, August 7. Barclays Capital initiated Ophthotech Corporation (NASDAQ:OPHT) rating on Wednesday, April 27. Barclays Capital has “Overweight” rating and $85 target. The company was maintained on Monday, December 14 by Chardan Capital Markets.

Analysts await Ophthotech Corporation (NASDAQ:OPHT) to report earnings on July, 25. They expect $-0.40 earnings per share, up 35.48% or $0.22 from last year’s $-0.62 per share. After $-0.36 actual earnings per share reported by Ophthotech Corporation for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.

Ophthotech Corporation (NASDAQ:OPHT) Institutional Positions Chart